Dr Stavros has over 30 years of industry experience in the design, implementation, management and regulatory submission of nonclinical drug development from lead optimization to market approval. She has extensive knowledge and expertise in strategic nonclinical development program design and execution, GLP compliance, clinical bioanalysis and pharmacokinetic assessment, contract research organization (CRO) selection and management, and in the writing and submission of the nonclinical regulatory documents (foreign and domestic). Dr Stavros has personally taken a small molecule from target identification, through lead optimization, into first in man studies and on to market approval.

Prior to joining Renibus Therapeutics Dr. Stavros was VP of Nonclinical Development at ZS Pharma where she had sole responsibility for the nonclinical development of Lokelma. 

Other positions included Senior Director of Nonclinical Development at Encysive Pharmaceuticals, Inc. where she oversaw the strategic development, execution and regulatory submissions of the nonclinical development programs for 4 therapeutic areas. She also was responsible for all clinical bioanalysis, reporting and pharmacokinetic evaluation and wrote the clinical drug-drug interaction plan.  During her tenure she successfully filed 8 IND’s and 1 NDA.

Prior to Encysive, Fiona worked as a manager at Immunopharmaceutics Inc., an early development pharmaceutical company and Synbiotics Corp., which specialized in veterinary diagnostics. 

Fiona obtained a Bachelor of Science (Hons) degree and Ph.D. in Pharmacology from the University of Edinburgh. She has over 30 peer reviewed scientific publications.